Cellectar Biosciences remains a high-risk, pre-revenue biotechnology firm whose long-term viability is tethered to the successful clinical advancement of its proprietary PDC platform. While the company continues to prioritize R&D, the lack of commercial revenu...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$0.57-9.6% vs -$0.52 | — vs $12M |
Q2 2026 May 14, 2026 | -$1.33+29.4% vs -$1.89 | — vs $8M |
Q2 2026 Mar 4, 2026 | -$0.53+55.5% vs -$1.19 | — vs $13M |
Q4 2025 Nov 13, 2025 | -$1.41+26.2% vs -$1.91 | — vs — |
Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy Transcript
Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript
Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program
Cellectar Biosciences, Inc. (NASDAQ: CLRB - Get Free Report) has been given an average rating of "Moderate Buy" by the five research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating on
Benchmark CLRB against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Cellectar Biosciences, Inc. (CLRB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.05 | $25.08M | -0.25 | — | — | -179.99% | — | |
| $17.38 | $41.95M | -0.38 | -3.5% | -624.59% | -16.12% | — | |
| $7.87 | $231.23M | -1.57 | -92.81% | -10422.48% | — | — | |
| $222.30 | $32.25B | — | 9.85% | 26.94% | 23.88% | — | |
| $123.96 | $9.13B | -21.19 | — | — | -42.78% | — | |
| $8.40 | $349.8M | -2470.59 | 10.37% | 69.76% | — | — |
Cellectar Biosciences, Inc. (CLRB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Cellectar Biosciences, Inc. (CLRB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Jul 10, 2026·SEC
May 18, 2026·SEC
Get notified when CLRB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Cellectar Biosciences, Inc. (CLRB) stock FAQ — growth, dividends, profitability & financials explained
Cellectar Biosciences, Inc. (CLRB) reported a net loss of $22.3M for fiscal year 2025.
Cellectar Biosciences, Inc. (CLRB) has a return on equity (ROE) of -180.0%. Negative ROE indicates the company is unprofitable.
Cellectar Biosciences, Inc. (CLRB) had negative free cash flow of $19.5M in fiscal year 2025, likely due to heavy capital investments.
